Efficiency and safety of subconjunctival injection of anti-VEGF agent – bevacizumab – in treating dry eye
Authors Jiang X, Lv H, Qiu W, Liu Z, Li X, Wang W
Received 26 March 2015
Accepted for publication 22 April 2015
Published 12 June 2015 Volume 2015:9 Pages 3043—3050
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 2
Editor who approved publication: Professor Shu-Feng Zhou
Xiaodan Jiang,* Huibin Lv,* Weiqiang Qiu, Ziyuan Liu, Xuemin Li, Wei Wang
Department of Ophthalmology, Peking University Third Hospital, Beijing, People’s Republic of China
*These authors contributed equally as first authors
Purpose: Dry eye is a chronic inflammatory ocular surface disease with high prevalence. The current therapies for dry eye remain to be unspecific and notcomprehensive. This study aims to explore safety and efficacy of a novel treatment – subconjunctival injection of bevacizumab – in dry eye patients.
Methods: Sixty-four eyes of 32 dry eye patients received subconjunctival injection of 100 μL 25 mg/mL bevacizumab. Dry eye symptoms, signs (corrected visual acuity, intraocular pressure, conjunctival vascularity, corneal staining, tear break-up time, Marx line score, and blood pressure), and conjunctival impression cytology were evaluated 3 days before and 1 week, 1 month, and 3 months after injection.
Results: Significant improvements were observed in dry eye symptoms, tear break-up time, and conjunctival vascularization area at all the visits after injection compared to the baseline (P<0.05). The density of the goblet cell increased significantly at 1 month and 3 months after injection (P<0.05). There was no visual and systemic threat observed in any patient.
Conclusion: Subconjunctival injection of 100 µL 25 mg/mL bevacizumab is a safe and efficient treatment for ocular surface inflammation of dry eye disease.
Keywords: anti-VEGF, bevacizumab, dry eye, ocular surface inflammation, subconjunctival
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]